Mechanistic insights into p53-promoted RNA-RNA annealing

Journal of Molecular Biology

Volumn 266, Issue 4, 1997, Pages 677-687

  Nedbal, Wolfgang ^a   Frey, Manfred ^a   Willemann, Bernhard ^a   Zentgraf, Hanswalter ^a   Sczakiel, Georg ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Macromolecular assembly; p53 protein; p53 RNA interaction; Protein RNA interactions; RNA RNA annealing

Indexed keywords

MAGNESIUM; NUCLEASE; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; ENTHALPY; ENTROPY; PRIORITY JOURNAL; PROTEIN RNA BINDING; PROTEIN SECONDARY STRUCTURE; RNA RNA ANNEALING; RNA STRUCTURE; STOICHIOMETRY; THERMODYNAMICS;

EID: 0031557393     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1996.0813     Document Type: Article

References (60)

1. Altmann M., Wittmer B., Methot N., Sonenberg N., Trachsel H. The Saccharomyces cerevisiae translation initiation factor Tif3 and its mammalian homologue, eIF-4B, have RNA annealing activity. EMBO J. 14:1995;3820-3827.
2. Bakalkin G., Yakovleva T., Selivanova G., Magnusson K. P., Szekeley L., Kiseleva E., Klein G., Terenius L., Wiman K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl Acad. Sci. USA. 91:1994;413-417.
3. Bargonetti J., Friedman P. N., Kern S. E., Vogelstein B., Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell. 65:1991;1083-1091.
4. Bargonetti J., Reynisdottir I., Friedman P. N, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1992;1886-1898.
5. Bischoff J. R., Friedman P. N., Marshak D. R., Prives C., Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl Acad. Sci. USA. 87:1990;4766-4770.
6. Cobianchi F., Calvio C., Stoppini M., Buvoli M., Riva S. Phosphorylation of human hnRNP protein A1 abrogates in vitro strand annealing activity. Nucl. Acids Res. 21:1993;949-955.
7. Coetzee T., Herschlag D., Belfort M. Escherichia coli proteins, including ribosomal protein S12, facilitate in vitro splicing of phage T4 introns by acting as RNA chaperones. Genes Dev. 8:1994;1575-1588.
8. Cowan J. A. Introduction to the biological chemistry of magnesium ion. The Biological Role of Magnesium. 1995;Verlag Chemie, Weinheim.
9. Dib-Hajj F., Khan R., Giedroc D. P. Retroviral nucleocapsid proteins possess potent nucleic acid strand renaturation activity. Protein Sci. 2:1993;231-243.
10. Draper D. E. Protein-RNA recognition. Annu. Rev. Biochem. 64:1995;593-620.
11. El Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1:1992;45-49.
12. Fields S., Jang S. K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
13. Funk W. D., Pak D. T., Karas R. H., Wright W. E., Shay J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:1992;2866-2871.
14. Gesteland R. F., Atkins. The RNA World. 1993;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
15. Herschlag D., Khosla M., Tsuchihashi Z, Karpel R. L. A RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis (published erratum appears in EMBO J. (1994) Aug 15;13 (16):3926). EMBO J. 13:1994;2913-2924.
16. Homann, M. 1995, Hemmung der HIV-1-Replikation durch Antisense-RNA und Ribozyme: Einfluβ von RNA-Sekundästrukturen, Dissertation Universität Heidelberg, Germany.
17. Homann M., Rittner K., Sczakiel G. Complementary large loops determine the rate of RNA duplex formation in vitro in the case of an effective antisense RNA directed against the human immunodeficiency virus type 1. J. Mol. Biol. 233:1993;7-15.
18. Kaslan E., Heyer W. D. Schizosaccharomyces pombe fatty acid synthase mediated DNA exchange in vitro. J. Biol. Chem. 269:1994;14103-14110.
19. Kern S. E., Kinzler K. W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
20. Khochbin S., Lawrence J. J. An antisense RNA involved in p53 mRNA maturation in murine erythroleukemia cells induced to differentiate. EMBO J. 8:1989;4107-4114.
21. Kumar A., Wilson S. H. Studies of the strand-annealing activity of mammalian hnRNP complex protein A1. Biochemistry. 29:1990;10717-10722.
22. Labuda D., Poerschke D. Multistep mechanism of codon recognition by transfer ribonucleic acid. Biochemistry. 19:1980;3799-3805.
23. Lapadat-Tapolsky M., Pernelle C., Borie C., Darlix J. L. Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. Nucl. Acids Res. 23:1995;2434-2441.
24. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235-1246.
25. Madhani H. D., Guthrie C. Dynamic RNA-RNA interactions in the spliceosome. Annu. Rev. Genet. 28:1994;1-26.
26. McCormick F., Clark R., Harlow E., Tjian R. SV40 T antigen binds specifically to a cellular 53 K protein in vitro. Nature. 292:1981;63-65.
27. Meek D. W., Simon S., Kikkawa U., Eckhart W. The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J. 9:1990;3253-3260.
28. Moll U. M., Riou G., Levine A. J. Two direct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl Acad. Sci. USA. 89:1992;7262-7266.
29. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:1995;4442-4449.
30. Nedbal W., Sczakiel G. Facilitators of RNA-RNA annealing: implications for the catalytic cycle of hammerhead ribozymes. Biochem. Soc. Trans. 24:1996;615-618.
31. Oberosler P., Hloch P., Ramsperger U., Stahl H. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 12:1993;2389-2396.
32. Pavletich N. P., Chambers K. A., Pabo C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:1993;2556-2564.
33. Persson C., Wagner E. G., Nordstroem K. Control of replication of plasmid R1: formation of an initial transient complex is rate-limiting for antisense RNA-target RNA pairing. EMBO J. 9:1990;3777-3785.
34. Pontius B. W., Berg P. Renaturation of complementary DNA strands mediated by purified mammalian heterogeneous nuclear ribonucleoprotein A1 protein: implications for a mechanism for rapid molecular assembly. Proc. Natl Acad. Sci. USA. 87:1990;8403-8407.
35. Pontius B. W., Berg P. Rapid renaturation of complementary DNA strands mediated by cationic detergents: a role for high-probabilty binding domains in enhancing the kinetics of molecular assembly processes. Proc. Natl Acad. Sci. USA. 88:1991;8237-8241.
36. Pörschke D., Eigen M. Co-operative non-enzymic base recognition. 3. Kinetics of the helix-coil transition of the oligoribouridylic-oligoriboadenylic acid system and of oligoriboadenylic acid alone at acidic pH. J. Mol. Biol. 62:1971;361-381.
37. Portman D. S., Dreyfuss G. RNA annealing activities in HeLa nuclei. EMBO J. 13:1994;213-221.
38. Ratner L., Haseltine W., Patarca R, Livak K. J., Starcich B., Josephs S. F., Doran E. R., Rafalski J. A., Whitehorn E. A., Baumeister K., Ivanoff L., Petteway S. R. Jr, Pearson M. L., Lautenberger J. A., Papas T. S., Ghrayeb J., Chang N. T., Gallo R. C., Wong-Staal F. Complete nucleotide sequence of the AIDS virus, HTL VIII. Nature. 313:1985;277-283.
39. Raycroft L., Wu H. Y., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogen. Science. 249:1990;1049-1051.
40. Rittner K., Burmester C., Sczakiel G. In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucl. Acids Res. 21:1993;1381-1387.
41. Romani A., Sarpa A. Regulation of cell magnesium. Arch. Biochem. Biophys. 1:1992;1-12.
42. Sczakiel G., Pawlita M., Rittner K., Homann M. Antisense RNA-mediated inhibition of the replication of the human immunodeficiency virus type 1. Ann. NY Acad. Sci. 660:1992;268-271.
43. Shaulian E., Zauberman A., Ginsberg D., Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:1992;5581-5592.
44. Shaulsky G., Goldfinger N., Peled A., Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ. 2:1991;661-667.
45. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
46. Steinmeyer IK., Deppert W. DNA binding properties of murine p53. Oncogene. 3:1988;501-507.
47. Stenger J. E., Mayr G. A., Mann K., Tegtmeyer P. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 2:1992;102-106.
48. Stürzbecher H. W., Maimets T., Chumakov P., Brain R., Addison C., Simanis V., Rudge K., Philp R., Grimaldi M., Court W. et al. p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene. 5:1990;795-781.
49. Stürzbecher H. W., Brian R., Addison C., Rudge K., Remm M., Grimaldi M., Keenan E., Jenkins J. R. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene. 7:1992;1513-1523.
50. Tomizawa J. Control of ColE1 plasmid replication: the process of binding of RNA I to the primer transcript. Cell. 38:1984;871-878.
51. Tsuchihashi Z, Brown P. O. DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. J. Virol. 68:1994;5863-5870.
52. Tsuchihashi Z., Khosla M., Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science. 262:1993;99-102.
53. Uhlenbeck O. C. Complementary oligonucleotide binding to transfer RNA. J. Mol. Biol. 65:1972;25-41.
54. Unger T., Nau M. M., Segal S., Minna J. D. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1992;1383-1390.
55. Volkmann M., Hofmann W. J., Müller M., Räth U., Otto G., Zentegraf H., Galle P. R. p53 overexpression is frequent in european hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene. 9:1994;195-204.
56. Wagner E. G., Simons R. W. Antisense control in bacteria, phages, and plasmids. Annu. Rev. Microbiol. 48:1994;713-742.
57. Wang Y., Reed M., Wang P., Stenger J. E., Mayr G., Anderson M. E., Schwedes J. F., Tegtmeyer P. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:1993;2575-2586.
58. Wu Y., Liu Y., Lee L., Miner Z., Kulesz Martin M. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13:1994;4823-4820.
59. Wu L., Bayle J. H., Elenbaas B., Pavletich N. P., Levine A. J. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell Biol. 15:1995;497-504.
60. Yoon K., Turner D. H., Tinoco I. The kinetics of codon-anticodon interaction in yeast phenylalanine transfer RNA. J. Mol. Biol. 99:1975;507-518.